Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the 22nd Annual Needham Virtual Healthcare Conference. The conference is being conducted in a virtual format, and the presentation will take place on Tuesday, April 18, 2023, at 12:45pm ET.
A live webcast of the presentation can be accessed under "Events" in the Investor section of the Company's website, https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the event.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024. At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...
The Canadian Cancer Society commends the increases in taxes on tobacco and e-cigarettes in today's federal budget. The budget increases tobacco taxes by $4.00 per carton of 200 cigarettes effective at midnight, and increases e-cigarette taxes by 12%...
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIREŽ (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Toronto Stock Exchange ("TSX") is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company's financial...
